Briefly
Dec 06, 2016

Five Breast Cancer Facts You Should Know

The San Antonio Breast Cancer Symposium, December 6 - 10, brings together academic researchers and health care professionals to share the latest research and advancements in the treatment/understanding of breast cancer.
 

Stories
Dec 05, 2016

New Ways to Treat Cancer: Combinations Could Change the Game

Oncology researcher Dr. Gary Gordon feels optimistic about the future of cancer treatment. Here’s why.

Briefly
Dec 02, 2016

Our Commitment to the Most Common Adult Leukemia

Learn more about the symptoms and treatment of chronic lymphocytic leukemia (CLL).

Stories
Dec 02, 2016

‘Patients Need To Move On With Their Lives’: Q&A With Lori Styles, M.D., Pharmacyclics

Graft-Versus-Host Disease literally adds insult to injury. Preventing it will ensure transplant patients can finally move on with their lives.
 

Briefly
Nov 29, 2016

AbbVie Honored with Global Citizen Award

International Medical Corps celebrates its partnership with AbbVie that brings medical, psycho-social and disaster support to vulnerable populations.
 

Stories
Nov 22, 2016

Need to Win Jeopardy and Conquer Cancer? Call Watson

The global burden of cancer is expected to grow over the next 15 years. Can artificial intelligence help tackle the complexities of the disease?
 
Stories
Nov 22, 2016

What You Don’t Know About Lymphoma and Why It Will Surprise You

Thought to be one disease, non-Hodgkin lymphoma is made up of more than 65 subtypes. Lymphoma Coalition CEO Karen Van Rassel explains the importance of knowing your subtype. 
 

Briefly
Nov 17, 2016

AbbVie Proud of Our National Merit Scholars

We are pleased to participate in the National Merit Scholarship Program to recognize outstanding high school students of our employees’ families. 
 

VIEW ALL STORIES

PRESS RELEASES

Dec 08, 2016

European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

- VENCLYXTO™ (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor1

Dec 06, 2016

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

NORTH CHICAGO, Ill., Dec. 6, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib (IMBRUVICA®) in patients with chronic graft-versus-host-disease (cGVHD), a serious and debilitating potential consequence of stem cell or bone marrow transplant,1 who failed prior systemic therapy. The study found ibrutinib demonstrated efficacy, sustained responses and reduced symptom severity, with an overall response rate (ORR) of 67%.2 Final results from this study presented today as a late-breaking oral presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (abstract #LBA-3). IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

Dec 05, 2016

New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)

NORTH CHICAGO, Ill., Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced efficacy and safety findings from a Phase 2 study demonstrating that nearly half (48%) of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) had a complete or partial response with single-agent ibrutinib (IMBRUVICA®), as assessed by Independent Review Committee (IRC) investigators. The median duration of response was not reached.1 These data will be presented today in an oral presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (abstract #1213). IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

MORE PRESS RELEASES